Category Archives: Eli Lilly

Eli Lilly


Eli Lilly

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Eli Lilly

Colonel Eli Lilly in 1885
Born July 8, 1838(1838-07-08) Baltimore, Maryland
Died June 6, 1898 (aged 59)
Indianapolis
, Indiana
Cause of death Cancer
Resting place Crown Hill Cemetery
Indianapolis
, Indiana
Nationality American
Education Pharmacology
Alma mater Asbury College
Occupation Pharmaceutical Chemist
Soldier

Industrialist
Known for Eli Lilly & co.
Philanthropy
Home town Indianapolis, Indiana
Title Colonel
Political party Republican
Religion Methodist
Spouse Emily Lemen (1860–1866)
Maria Cynthia Sloan (1869–1898)
Children Josiah K. Lilly, Sr.
Parents Esther & Gustavus Lilly
Relatives Eli Lilly (Grandson)
Josiah K. Lilly, Jr.
(Grandson)
Signature
Eli Lilly (July 8, 1838 – June 6, 1898) was an American soldier, pharmaceutical chemist, industrialist, entrepreneur, and founder of the Eli Lilly and Company pharmaceutical corporation. Lilly enlisted in the Union Army during the American Civil War; he recruited a company of men to serve with him in an artillery battery, was later promoted to colonel, and was given command of a cavalry unit. He was captured near the end of the war and held as a prisoner of war until its conclusion. After the war, he attempted to run a plantation in Mississippi, but failed and returned to his pharmacy profession after the death of his wife. Lilly remarried and worked in several pharmacies with partners before opening his own business in 1876 with plans to manufacture drugs and market them wholesale to pharmacies.
His company was successful and he soon became wealthy after making numerous advances in medicinal drug manufacturing. Two of the early advances he pioneered were creating gelatin capsules to hold medicine and fruit flavoring for liquid medicines. Eli Lilly & Company was one of the first pharmaceutical firms of its kind; it staffed a dedicated research department and put in place numerous quality-assurance measures.
Using his wealth, Lilly engaged in numerous philanthropic pursuits. He turned over the management of the company to his son in 1890 allowing himself to continue his engagement in charity and civic advancement in his primary focus. He helped found the organization that became the Indianapolis Chamber of Commerce, was the primary patron of Indiana’s branch of the Charity Organization Society, and personally funded the creation of the city’s children’s hospital which was later expanded by the state to become the Riley Children’s Hospital. He continued his active involvement with many organizations until his death from cancer in 1898.
Lilly was an advocate of federal regulation of the pharmaceutical industry, and many of his suggested reforms were enacted into law in 1906, resulting in the creation of the Food and Drug Administration. He was also among the pioneers of the concept of prescriptions, and helped form what became the common practice of giving addictive or dangerous medicines only to people who had first seen a physician. The company he founded has since grown into one of the largest and most influential pharmaceutical corporations in the world, and the largest corporation in Indiana. Using the wealth generated by the company, his son and grandsons created the Lilly Endowment to continue Lilly’s legacy of philanthropy. The endowment remains one of the largest charitable benefactors in the world.

Contents

[show]

Antipsychotics Pseuodoscience Death and Symbolic name fraud


Antipsychotics

From Wikipedia, the free encyclopedia
  (Redirected from Major tranquilizers)
Jump to: navigation, search
An antipsychotic (or neuroleptic) is a tranquilizing psychiatric medication primarily used to manage psychosis (including delusions or hallucinations, as well as disordered thought), particularly in schizophreniabipolar disorder. A first generation of antipsychotics, known as typical antipsychotics, was discovered in the 1950s. Most of the drugs in the second generation, known as atypical antipsychotics, have been developed more recently, although the first atypical antipsychotic, clozapine, was discovered in the 1950s and introduced clinically in the 1970s. Both generations of medication tend to block receptors in the brain’s dopamine pathways, but antipsychotic drugs encompass a wide range of receptor targets. and
A number of harmful and undesired (adverse) effects have been observed, including lowered life expectancy, weight gain, enlarged breasts and milk discharge in men and women (hyperprolactinaemia), lowered white blood cell count (agranulocytosis), involuntary repetitive body movements (tardive dyskinesia), diabetes, an inability to sit still or remain motionless (tardive akathisia), sexual dysfunction, a return of psychosis requiring increasing the dosage due to cells producing more neurochemicals to compensate for the drugs (tardive psychosis), and a potential for permanent chemical dependence leading to psychosis much worse than before treatment began, if the drug dosage is ever lowered or stopped (tardive dysphrenia).
Temporary withdrawal symptoms including insomnia, agitation, psychosis, and motor disorders may occur during dosage reduction of antipsychotics, and can be mistaken for a return of the underlying condition.[1][2]

 History

The original antipsychotic drugs were happened upon largely by chance and then tested for their effectiveness. The first, chlorpromazine, was developed as a surgical anesthetic. It was first used on psychiatric patients because of its powerful calming effect; at the time it was regarded as a “chemical lobotomy“. Lobotomy at the time was used to treat many behavioral disorders, including psychosis, although its effect was to markedly reduce behavior and mental functioning of all types. However, chlorpromazine proved to reduce the effects of psychosis in a more effective and specific manner than the extreme lobotomy-like sedation it was known for. The underlying neurochemistry involved has since been studied in detail, and subsequent antipsychotic drugs have been discovered by an approach that incorporates this sort of information.

Drug action

All antipsychotic drugs tend to block D2 receptors in the dopamine pathways of the brain. This means that dopamine released in these pathways has less effect. Excess release of dopamine in the mesolimbic pathway has been linked to psychotic experiences. It is the blockade of dopamine receptors in this pathway that is thought to control psychotic experiences.
Typical antipsychotics are not particularly selective and also block dopamine receptors in the mesocortical pathway, tuberoinfundibular pathway, and the nigrostriatal pathway. Blocking D2 receptors in these other pathways is thought to produce some of the unwanted side effects that the typical antipsychotics can produce (see below). They were commonly classified on a spectrum of low potency to high potency, where potency referred to the ability of the drug to bind to dopamine receptors, and not to the effectiveness of the drug. High-potency antipsychotics such as haloperidol, in general, have doses of a few milligrams and cause less sleepiness and calming effects than low-potency antipsychotics such as chlorpromazine and thioridazine, which have dosages of several hundred milligrams. The latter have a greater degree of anticholinergic and antihistaminergic activity, which can counteract dopamine-related side effects.
Atypical antipsychotic drugs have a similar blocking effect on D2 receptors. Some also block or partially block serotonin receptors (particularly 5HT2A, C and 5HT1A receptors):ranging from risperidone, which acts overwhelmingly on serotonin receptors, to amisulpride, which has no serotonergic activity. The additional effects on serotonin receptors may be why some of them can benefit the “negative symptoms” of schizophrenia.[74]

Controversy

Use of this class of drugs has a history of criticism in residential care. As the drugs used can make patients calmer and more compliant, critics claim that the drugs can be overused. Outside doctors can feel under pressure from care home staff.[81] In an official review commissioned by UK government ministers it was reported that the needless use of anti-psychotic medication in dementia care was widespread and was linked to 1800 deaths per year.[82][83] In the US, the government has initiated legal action against the pharmaceutical company Johnson and Johnson for allegedly paying kickbacks to Omnicare to promote its antipsychotic Risperidone (Risperdal) in nursing homes.[84]
There is some controversy over maintenance therapy for schizophrenia.[2][85] A review of studies about maintenance therapy concluded that long-term antipsychotic treatment was superior to placebo in reducing relapse in individuals with schizophrenia, although some of the studies were small.[86] A review of major longitudinal studies in North America found that a moderate number of patients with schizophrenia were seen to recover over time from their symptoms, raising the possibility that some patients may not require maintenance medication.[85] It has also been argued that much of the research into long-term antipsychotic maintenance may be flawed due to failure to take into account the role of antipsychotic withdrawal effects on relapse rates.[2]
There has also been controversy about the role of pharmaceutical companies in marketing and promoting antipsychotics, including allegations of downplaying or covering up adverse effects, expanding the number of conditions or illegally promoting off-label usage; influencing drug trials (or their publication) to try to show that the expensive and profitable newer atypicals were superior to the older cheaper typicals that were out of patent. For example in the US, Eli Lilly recently pleaded guilty to violating US laws for over a decade in regard to Zyprexa (olanzapine), and was ordered to pay $1.42 billion to settle criminal and civil allegations, including the biggest criminal fine for an individual corporation ever imposed in US history; while Astrazeneca Seroquel (quetiapine), amidst federal investigations of its marketing practices.[87] By expanding the conditions for which they were indicated, Astrazeneca’s Seroquel and Eli Lilly’s Zyprexa had become the biggest selling antipsychotics in 2008 with global sales of $5.5 billion and $5.4 billion respectively.[11] is facing about 9,000 personal-injury lawsuits from more than 15,000 former users of
Some critics have also analyzed the use of alleged front organizations and conflicted patient “advocacy” groups funded by pharmaceutical companies that seek to set the mental health agenda, including the use of the law to force people to take antipsychotics against their will, often justified by claims about risk of violence.[88]